Medicare proposes covering a costly and controversial Alzheimer's drug, with some restrictions. It could have vast consequences for patients and enrollees.
Medicare has proposed covering the controversial and costly Alzheimer's drug Aduhelm only for those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Tuesday.
The agency's decision, the latest step in the drug's contentious path to market, would have far-reaching consequences both for millions of Alzheimer's patients and for tens of millions of Medicare enrollees. A final decision should be released by April 11."CMS has proposed an evidence-based coverage policy after experts reviewed all relevant publicly available evidence and feedback received from stakeholders," said Chiquita Brooks-LaSure, the agency's administrator.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patientsThe U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access.
Read more »
Medicare is about to make its most important coverage decision in years. Here’s how people with Alzheimer’s and others might be affected.A controversial new drug is roiling the medical community and driving up Medicare premiums.
Read more »
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Read more »
Medicare Told to Reassess Premium Hike for Alzheimer's DrugU.S. health secretary Xavier Becerra is ordering Medicare to reassess a big premium increase facing millions of seniors this year
Read more »
Medicare told to reassess premium hike for Alzheimer's drugHealth secretary orders Medicare to reassess a big premium increase facing millions of seniors this year, attributed in large part to a pricey new Alzheimer's drug with questionable benefits.
Read more »
Government May Scale Back Medicare Part B Premium IncreaseMedicare officials were instructed Monday to reassess the standard monthly amount due to a reduction in the cost of a drug that caused half the premium jump.
Read more »